Escolar Documentos
Profissional Documentos
Cultura Documentos
Objective
To review the causes of primary immunodeficiency among adults To have an overview of common variable immunodeficiency
Clinical Presentations
ed susceptibility to infections recurrent, severe, opportunistic Autoimmune diseases - AITP, AIHA, RA, SLE, etc Inflammatory disorders - IBD, sarcoidosis
Chronic Mucocutaneous candidiasis, Salmonella diarrhea, Campylobacter enteritis, Osteomyelitis, Septic arthritis, Nocardia brain abscess, etc.
Autoimmunity (n=248)
AITP AIHA RA JRA Anti-IgA SS PBC Pernicious anemia Hyperthyroid disease SLE Vasculitis autoimmune diseases 15 12 5 4 7 2 3 3 2 2 365 56
Malignancy
NHL 7.7% - mostly extranodal, all B cell type Others Waldenstroms macroglobulinemia Hodgkins disease Adenocarcinoma - stomach, ovary, colon Sq cell Ca - vagina, skin, mouth, lung Ca - breast, prostate Melanoma
GI Diseases (n=248*)
Nodular lymphoid hyperplasia UC Ulc. Proctitis Crohns disease Malabsorption, no other diag. Giardiasis Malnutrition needing TPN Campylobacter enteritis *Clin Immunol 1999; 92:34-48 10 4 3 9 10 8 5 5
Laboratory Abnormalities
IgG, mostly with IgA and IgM Lymphopenia 20% B cell numbers - mostly normal CD4/CD8 ratios, in CD4+CD45+ T cells levels of IL-4, IL6, soluble CD8, CD25, 2microglobulin, HLA-DR, LFA-3 and ICAM-1 : secondary to infections 60% - ed proliferative responses to TCR stimulation and ed induction of gene expression for IL-2, IL-4, IL-5 and IFN-
Family Members
10% of patients - CVID or IgA deficiency is seen in more than one family member More likely to have IgA deficient children Possible linkages to HLA Class II or III genes
Differential Diagnosis
Hypogammaglobulinemia secondary to other disorders e.g. secondary to loss of Ig and other serum proteins in the urine & stool CLL, thymoma, other lymphoreticular malignancies Secondary to other drugs like phenytoin, cyclophosphamide Other primary immunodeficiency diseases e.g. XLA
Treatment
Early and aggressive antibiotic therapy, ongoing therapy for autoimmune and inflammatory disorders & surveillance for malignancy Replacement with IVIG: 400-500 mg/kg/month Prevents breakthrough infections, abnormal pulmonary function may improve, even if chronic lung damage is present